liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Prevalence of the apolipoprotein E epsilon 4 allele in amyloid beta positive subjects across the spectrum of Alzheimers disease
Lund Univ, Sweden.
Vrije Univ Amsterdam, Netherlands; Vrije Univ Amsterdam, Netherlands.
Maastricht Univ, Netherlands.
Univ Calif Berkeley, CA 94720 USA.
Vise andre og tillknytning
2018 (engelsk)Inngår i: Alzheimer's & Dementia, ISSN 1552-5260, E-ISSN 1552-5279, Vol. 14, nr 7, s. 913-924Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Introduction: Apolipoprotein E (APOE) epsilon 4 is the major genetic risk factor for Alzheimers disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid beta(A beta) pathology. Methods: We included 3451 A beta+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE epsilon 4 prevalence in relation to age, sex, education, and geographical location. Results: The APOE epsilon 4 prevalence was 66% in AD-type dementia, 64% in mild cognitive impairment, and 51% in cognitively normal, and it decreased with advancing age in A beta+ cognitively normal and A beta+ mild cognitive impairment (P amp;lt;.05) but not in A beta+ AD dementia (P =.66). The prevalence was highest in Northern Europe but did not vary by sex or education. Discussion: The APOE E4 prevalence in AD was higher than that in previous studies, which did not require presence of A beta pathology. Furthermore, our results highlight disease heterogeneity related to age and geographical location. (C) 2018 the Alzheimers Association. Published by Elsevier Inc. All rights reserved.

sted, utgiver, år, opplag, sider
ELSEVIER SCIENCE INC , 2018. Vol. 14, nr 7, s. 913-924
Emneord [en]
APOE; Prevalence; Amyloid; PET; CSF; Alzheimers disease; Mild cognitive impairment; Subjective cognitive decline; Age; Sex; Education; Geographical location
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-150288DOI: 10.1016/j.jalz.2018.02.009ISI: 000438783200009PubMedID: 29601787OAI: oai:DiVA.org:liu-150288DiVA, id: diva2:1239663
Merknad

Funding Agencies|AXA Research Fund; Fondation Universite Pierre et Marie Curie; "Fondation pour la Recherche sur Alzheimer", Paris, France; program "Investissements davenir" [ANR-10-IAIHU-06]; National Institutes of Health [P50 AG005133, RF1 AG025516, PO1 AG025204]; Marie Curie FP7 International Outgoing Fellowship [628812]; Instituto de Salud Carlos III (Fondo de InvestigaciOn Sanitario) [PI08/0139, PI12/02288, PI16/01652]; NIH/NIA [RF1 AG057570, AG035137, AG032554, AG022374, AG13616, AG12101, AG08051, NIH-HLB HL111724]; Instituto de Salud Carlos III (CIBERNED program)

Tilgjengelig fra: 2018-08-17 Laget: 2018-08-17 Sist oppdatert: 2018-08-17

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Søk i DiVA

Av forfatter/redaktør
Marcusson, Jan
Av organisasjonen
I samme tidsskrift
Alzheimer's & Dementia

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 64 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf